成都苑东生物制药股份有限公司 独立董事关于第三届董事会第十一次会议 相关事项的独立意见 我们作为成都苑东生物制药股份有限公司（以下简称"公司"）的独立董事， 根据《中华人民共和国公司法》（以下简称《公司法》）、《上海证券交易所科创板 股票上市规则》、《关于在上市公司建立独立董事制度的指导意见》、《公司章程》 及公司《独立董事工作制度》等有关规定，本着对公司、全体股东及投资者负责 的态度，基于独立判断的立场，对公司第三届董事会第十一次会议审议的《关于 以集中竞价交易方式回购股份方案的议案》发表独立意见如下： 1、公司本次回购股份符合《公司法》、《证券法》以及《上海证券交易所上 市公司自律监管指引第 7 号——回购股份》等法律法规、规范性文件以及《公司 章程》等有关规定，回购股份的审议和决策程序合法合规。 2、公司本次回购股份的用途为员工持股计划或股权激励，有利于充分调动 公司员工的积极性，提高团队凝聚力和竞争力，有效地将股东利益、公司利益和 员工利益紧密结合，促进公司稳定、健康、可持续发展，因此，本次股份回购具 有必要性。 3、本次回购资金来源为公司自有资金，不会对公司的经营、财务和未来发 展产生重大影响，公司 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥277,853,183.77, representing a year-on-year increase of 3.31%[5] - The net profit attributable to shareholders for the same period was ¥60,985,871.41, reflecting a growth of 13.35% compared to the previous year[5] - The basic earnings per share for Q1 2023 stood at ¥0.51, which is an increase of 13.33% year-on-year[6] - The net profit for Q1 2023 was CNY 60,985,871.41, representing an increase of 13.8% compared to CNY 53,801,911.59 in Q1 2022[19] - The operating profit for Q1 2023 was CNY 68,278,212.94, up from CNY 57,338,282.15 in the same period last year, indicating a growth of 19.4%[22] - The total operating expenses decreased to CNY 244,172,808.16 from CNY 282,959,361.73 in Q1 2022, a reduction of 13.7%[22] Research and Development - Research and development expenses totaled ¥51,336,628.31, accounting for 18.48% of operating revenue, a decrease of 1.34 percentage points from the previous year[6] - Research and development expenses increased to CNY 50,088,561.76, compared to CNY 45,192,135.02 in Q1 2022, reflecting an increase of 6.4%[22] Cash Flow and Assets - The net cash flow from operating activities was ¥32,933,694.58, showing a decline of 11.54% compared to the same period last year[5] - The cash flow from operating activities was CNY 32,933,694.58, a decrease from CNY 37,228,404.83 in the previous year, down by 11.5%[22] - The cash flow from investment activities showed a net outflow of CNY 289,811,019.34, improving from a net outflow of CNY 512,688,220.48 in Q1 2022[23] - Cash and cash equivalents decreased to RMB 620,514,361.50 from RMB 830,966,815.87 at the end of 2022, a decline of about 25.3%[13] - The company reported a cash and cash equivalents balance of CNY 614,284,188.64 at the end of Q1 2023, compared to CNY 590,296,812.64 at the end of Q1 2022, an increase of 4.0%[23] Shareholder Information - The total number of common shareholders at the end of the reporting period was 4,643[9] - The largest shareholder, Wang Ying, holds 41,900,000 shares, representing 34.89% of the total shares[9] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,098,765,523.95, an increase of 2.69% from the end of the previous year[6] - Current assets as of March 31, 2023, totaled RMB 1,742,813,162.60, compared to RMB 1,709,122,350.80 at the end of 2022, reflecting an increase of approximately 1.96%[13] - Total liabilities as of March 31, 2023, were RMB 592,973,210.53, up from RMB 573,080,516.96 at the end of 2022, representing an increase of about 3.2%[15] - Non-current assets totaled RMB 1,355,952,361.35, an increase from RMB 1,308,417,882.31 at the end of 2022, reflecting a growth of about 3.63%[14] - The company's retained earnings increased to RMB 881,245,083.61 from RMB 820,259,212.19 at the end of 2022, showing an increase of approximately 7.4%[15] Operating Costs - Total operating costs for Q1 2023 were RMB 226,451,481.30, slightly up from RMB 225,745,308.15 in Q1 2022, indicating a marginal increase of about 0.31%[17] - The company reported a net profit margin improvement, with total operating income growth outpacing total operating costs growth in Q1 2023[17] - The total revenue from operating activities was CNY 255,609,521.27, down from CNY 299,663,469.03 in Q1 2022, a decrease of 14.7%[22] Other Income - The company achieved other income of CNY 10,914,075.81, compared to CNY 6,027,818.28 in Q1 2022, marking an increase of 81.5%[22] - The company reported non-recurring gains of ¥14,655,333.08 for the period, after accounting for tax effects[7]

Financial Performance - The company's operating revenue for 2022 was approximately CNY 1.17 billion, representing a 14.43% increase from CNY 1.02 billion in 2021[23]. - The net profit attributable to shareholders for 2022 was approximately CNY 246.52 million, a 6.06% increase from CNY 232.43 million in 2021[23]. - The net profit after deducting non-recurring gains and losses was approximately CNY 164.70 million, reflecting a 20.16% increase from CNY 137.07 million in 2021[23]. - The company's total assets at the end of 2022 were approximately CNY 3.02 billion, an 8.73% increase from CNY 2.78 billion at the end of 2021[23]. - The basic earnings per share for 2022 was CNY 2.05, a 5.67% increase from CNY 1.94 in 2021[24]. - The company's net assets attributable to shareholders at the end of 2022 were approximately CNY 2.44 billion, a 6.67% increase from CNY 2.29 billion at the end of 2021[23]. - The total revenue for the reporting period reached ¥60,841.99 million, with a net profit of ¥12,454.41 million, reflecting a significant increase in performance[89]. - The company achieved total revenue of CNY 1,170,512,900.63, representing a year-on-year growth of 14.43%[113]. - The net profit attributable to shareholders was CNY 246,520,800, reflecting a year-on-year increase of 6.06%[113]. Research and Development - Research and development expenses accounted for 22.65% of operating revenue in 2022, up from 20.41% in 2021[24]. - The total R&D investment for the year reached ¥265.14 million, an increase of 27.02% compared to the previous year[74]. - The proportion of R&D investment to operating income rose to 22.65%, up by 2.24 percentage points from the previous year[74]. - The company has over 10 Class 1 innovative drugs in research, with 3 currently undergoing clinical trials, including the oral long-acting hypoglycemic drug, Yograstatin tablets[50][51]. - The company is focusing on innovative drug formulation techniques, achieving a stable production process for EP-0112T, a nasal spray with significant technical challenges[91]. - The company has reported a total R&D investment of 81,481.69 million RMB, representing 29.38% of its operating revenue, which is significantly higher than the industry average[173]. - The company's R&D investment as a percentage of net assets was 10.85%, indicating a strong commitment to innovation and development[173]. - The company capitalized 12.96% of its R&D expenditures, reflecting a strategic approach to managing its research investments[173]. Market Position and Strategy - The company has a strong market position, with three of its main products ranking first in market share, including sodium namifen injection, ibuprofen injection, and ibandronic acid sodium injection[62]. - The company is focusing on building a differentiated competitive advantage in innovative drug products, particularly in the fields of anesthesia and oncology[36][37]. - The company is actively expanding its international presence, particularly in the opioid detoxification and emergency medication product lines[55]. - The company is focusing on integrating raw materials and formulations to ensure supply chain security amid global uncertainties and increasing competition in the biopharmaceutical sector[65]. - The company is strategically expanding its CMO/CDMO business to enhance profitability and strengthen its integrated supply chain capabilities[98]. - The company aims to maintain competitiveness under centralized procurement policies by enhancing operational efficiency and continuously launching new products[146]. - The company is focusing on expanding its product portfolio with new drug approvals and ongoing clinical trials for various therapeutic areas[160]. Risks and Compliance - The company has detailed various risks and countermeasures in its annual report, urging investors to pay attention to investment risks[4]. - The company emphasizes that forward-looking statements do not constitute substantive commitments to investors[7]. - The company faces risks from national volume-based procurement and medical insurance payment adjustments, which may lead to price reductions for some products[105]. - The company has implemented a complete quality management system from drug development to commercial production, ensuring strict quality control[99]. Corporate Governance - The company has received a standard unqualified audit report from Zhonghui Certified Public Accountants[5]. - The company does not have any non-operating fund occupation by controlling shareholders or related parties[8]. - There are no violations of decision-making procedures for providing guarantees[9]. - The company has not reported any instances of more than half of the board members being unable to guarantee the authenticity of the annual report[9]. - The company has not disclosed any special arrangements for corporate governance[9]. Internationalization and Innovation - The internationalization strategy has seen the completion of 2 ANDA submissions, with the hydrochloride injection of Nalfurafine and Nicardipine receiving priority review and acceptance from the FDA[39][40]. - The company has successfully passed the Korean MFDS certification and FDA inspections for raw materials, marking significant progress in internationalization[43]. - The company is committed to internationalization, with plans to complete five international registration projects and enhance its product pipeline for the U.S. market[198]. - The company is focusing on innovation and the development of next-generation biotechnologies to enhance its product offerings[191]. Financial Management - Government subsidies accounted for CNY 65,927,300, which is 25.16% of the total profit, indicating potential risk if policies change[112]. - Operating costs increased by 36.77% year-on-year, primarily due to higher product sales volumes[115]. - The company's investment activities generated a net cash outflow of CNY 405,702,351.20, primarily due to increased construction investments[115]. - The net cash flow from financing activities improved to ¥39,696,297.46 from -¥56,396,555.50, mainly due to increased short-term borrowings and discounted notes receivable[136]. Talent Development - The company has established a comprehensive talent development strategy, including the establishment of a Shanghai Research Institute to attract top talent and enhance innovation capabilities[46]. - The company has a research and development team of over 400 people and has established a national-level enterprise technology center and postdoctoral research workstation[95]. - The R&D personnel count increased to 407, representing 30.76% of the total workforce, with an average salary of ¥23.11 million per person[94].

证券代码：688513 证券简称：苑东生物 公告编号：2023-017 成都苑东生物制药股份有限公司 关于召开 2022 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （三） 会议召开方式：上证路演中心网络互动 重要内容提示： 成都苑东生物制药股份有限公司（以下简称"公司"）已于 2023 年 4 月 13 日 发布公司 2022 年年度报告及 2022 年度利润分配预案，为加强与投资者的深入交 流，使投资者更加全面、深入地了解公司经营成果、财务指标等情况，公司计划 于 2023 年 04 月 21 日（星期五）上午 11:00 - 12:00 举行 2022 年度业绩暨现金分 红说明会，就投资者关心的问题进行交流，欢迎广大投资者积极参与。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成果、 财务指标及 2022 年度现金分红的具体情况与投资者进行互动交流和沟通，在信 息披露允许的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （ ...

Financial Performance - The company's revenue for Q3 2022 was ¥322,179,501.72, representing a year-over-year increase of 17.27%[6] - Net profit attributable to shareholders for Q3 2022 was ¥60,856,356.20, showing a decrease of 11.46% compared to the same period last year[6] - The net profit excluding non-recurring gains and losses for Q3 2022 was ¥38,517,219.50, an increase of 21.54% year-over-year[6] - Total operating revenue for the first three quarters of 2022 reached ¥897,590,018.32, an increase of 16.1% compared to ¥773,436,181.18 in the same period of 2021[24] - Net profit for the first three quarters of 2022 was ¥195,492,474.81, representing a growth of 5.5% from ¥186,075,903.15 in 2021[31] - Basic earnings per share for Q3 2022 were ¥0.51, down 10.53% compared to the same period last year[10] - Basic earnings per share for the first three quarters of 2022 were ¥1.63, compared to ¥1.55 in the same period of 2021[33] Research and Development - R&D investment totaled ¥75,772,263.90 in Q3 2022, up 41.55% from the previous year, accounting for 23.52% of revenue[10] - Research and development expenses for the first three quarters of 2022 amounted to ¥165,078,988.64, up 11.6% from ¥147,822,178.55 in the previous year[27] Assets and Liabilities - Total assets at the end of Q3 2022 reached ¥3,003,472,092.39, an increase of 8.22% from the end of the previous year[10] - The company's total current liabilities increased to ¥563,972,583.20 from ¥432,458,963.97, which is an increase of approximately 30.4%[22] - The total liabilities as of the end of the reporting period were ¥609,933,988.70, an increase from ¥483,601,755.82 in the previous year[24] - The total equity attributable to shareholders reached ¥2,393,538,103.69, up from ¥2,291,664,728.59 in 2021[24] Cash Flow - The company reported a net cash flow from operating activities of ¥141,346,062.05 for the year-to-date period, a decrease of 2.09% year-over-year[10] - Cash inflow from operating activities totaled ¥981,016,081.53 in the first three quarters of 2022, an increase from ¥909,989,358.80 in 2021[36] - The net cash flow from operating activities was $141,346,062.05, a decrease from $144,363,177.82 in the previous period[37] - Cash outflow from investing activities totaled $2,310,797,186.24, down from $3,297,696,338.54 year-over-year[37] - The net cash flow from investing activities was -$673,657,053.10, an improvement from -$943,287,000.18 in the prior period[37] - Cash inflow from financing activities amounted to $147,373,150.35, compared to $10,000,000.00 previously[37] - The net cash flow from financing activities was $52,188,019.78, a recovery from -$76,362,236.06 in the last period[37] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,138[13] Other Financial Metrics - The weighted average return on equity for Q3 2022 was 2.57%, a decrease of 0.54 percentage points year-over-year[10] - Government subsidies recognized in Q3 2022 amounted to ¥17,921,133.78, contributing to non-recurring gains[10] - The company's cash and cash equivalents decreased to ¥559,858,478.86 from ¥1,050,695,494.02 year-over-year, representing a decline of approximately 46.8%[19] - The trading financial assets increased significantly to ¥766,076,763.67 from ¥453,840,935.17, marking an increase of approximately 68.8%[19] - Accounts receivable rose to ¥137,554,068.67 from ¥112,427,878.56, reflecting an increase of about 22.3%[19] - The company's inventory increased to ¥123,781,058.87 from ¥103,682,790.76, representing an increase of about 19.4%[19] - The company's long-term equity investments were recorded at ¥98,030,208.71, with no previous year data available for comparison[22] - The company reported a significant increase in other non-current financial assets, totaling ¥22,000,000.00, with no previous year data available[22] Business Developments - The company has not reported any significant new product developments or market expansions during the reporting period[16] - There were no significant mergers or acquisitions disclosed in the third quarter report[16]

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 25%[19] - The net profit attributable to shareholders was RMB 100 million, with a growth rate of 15% compared to the same period last year[19] - The company's operating revenue for the first half of 2022 was RMB 575,410,516.60, representing a 15.38% increase compared to RMB 498,701,178.06 in the same period last year[26] - The net profit attributable to shareholders for the same period was RMB 134,636,118.61, up 14.74% from RMB 117,343,408.61 year-on-year[26] - The net profit after deducting non-recurring gains and losses increased by 25.44%, reaching RMB 105,094,083.93 compared to RMB 83,782,428.46 in the previous year[26] - The company's cash flow from operating activities saw a significant increase of 52.84%, totaling RMB 96,862,879.24, compared to RMB 63,375,926.37 in the same period last year[26] - The company maintains a strong cash position with RMB 200 million in cash reserves, ensuring liquidity for ongoing operations and investments[19] - The company reported a total revenue of 21,564.6 million, with a year-on-year increase of 62,100.39 million and a net profit of 4,942.69 million, representing a growth of 7%[90] - The company achieved operating revenue of 575.41 million yuan, an increase of 15.38% year-on-year[106] - The net profit attributable to the parent company was 134.64 million yuan, up 14.74% year-on-year, driven by increased sales of key products[106] Research and Development - The company is investing RMB 50 million in R&D for innovative drug development, focusing on competitive generic therapies[19] - The company's R&D investment accounted for 20.32% of operating revenue, an increase of 1.41 percentage points compared to 18.91% in the previous year[30] - The company's R&D expenditure reached 117 million CNY, accounting for 20.32% of annual revenue[63] - The total R&D investment amounted to ¥116,898,207.13, representing a 23.98% increase compared to ¥94,290,505.20 in the same period last year[73] - The R&D team expanded to 370 personnel, with a slight decrease in the proportion of R&D staff to total employees at 29.41%[5] - The company has over 50 ongoing projects, with 20% being innovative drug projects, including one Class 1 new drug in Phase III clinical trials[101] - The company has established a complete quality management system for drug development and commercial production, with multiple products certified by the FDA and EMA[103] - The company is focusing on expanding its capabilities in biopharmaceuticals, with ongoing development of monoclonal antibodies and dual-specific antibodies[110] - The company has submitted a total of 7 registration applications for formulations and APIs, and received 2 new domestic invention patents, enhancing its product pipeline and market competitiveness[111] Market Expansion and Product Development - User data indicated an increase in active users by 30%, reaching a total of 1.5 million users by the end of June 2022[19] - The company plans to launch two new products in Q4 2022, aiming to capture a larger market share in the biopharmaceutical sector[19] - Future outlook includes a projected revenue growth of 20% for the second half of 2022, driven by new product launches and market expansion strategies[19] - Market expansion efforts include entering two new international markets by the end of 2022, targeting a 10% increase in overseas sales[19] - The company is focused on expanding its product portfolio in the fields of anesthesia, diabetes, cardiovascular, and oncology, aiming to meet unmet clinical needs domestically and internationally[34] - The company is actively pursuing clinical trials and research to advance its product pipeline, with several projects at various stages of development[81] - The company is focusing on expanding its product portfolio in the cardiovascular and analgesic markets, with several products already submitted for registration[83][85] Innovation and Technology - The company has successfully commercialized 32 high-end chemical drugs, including 5 domestic first generic products and 22 products that have passed consistency evaluation[35] - The company has developed six core technologies, including drug crystal form integration innovation and controlled-release technology[58] - The company has established a micro-reaction continuous flow technology platform, successfully achieving breakthroughs in key material synthesis[62] - The company has achieved significant technological advancements in the production of various injectable drugs, including overcoming challenges related to stability and purity[83] - The company is enhancing its sales model by improving its distribution network and academic promotion strategies to adapt to national drug procurement policies[49] Risk Management and Compliance - Risk factors identified include regulatory changes and market competition, with mitigation strategies outlined in the report[19] - The company has no plans for mergers or acquisitions in the near term, focusing instead on organic growth strategies[19] - The company emphasizes adherence to legal and regulatory requirements regarding share transfers, maintaining compliance with stock exchange rules[197] - The company commits to not reducing its shareholdings during specific periods related to major violations or delisting risks, ensuring shareholder confidence[197] Environmental Responsibility - The company was recognized as a national green factory in December 2021, indicating a commitment to environmental protection[166] - The wastewater treatment facility has a processing capacity of 300 cubic meters per day, while the actual discharge is 201 cubic meters per day[166] - The company has implemented measures to ensure that major pollutants are effectively treated during production processes[166] - The company has upgraded its wastewater treatment system to a capacity of 400 cubic meters per day, ensuring compliance with discharge standards[172] - The company has received pollution discharge permits valid until 2026 for its operations[177] - The company has maintained compliance with environmental regulations, with no instances of exceeding pollutant discharge limits reported during the reporting period[185]

Financial Performance - The company's operating revenue for Q1 2022 was ¥268,954,445.02, representing a year-on-year increase of 21.56%[6] - The net profit attributable to shareholders for Q1 2022 was ¥53,801,911.59, reflecting a growth of 24.28% compared to the same period last year[6] - The net profit after deducting non-recurring gains and losses was ¥41,879,428.99, with a year-on-year increase of 23.99%[6] - Basic and diluted earnings per share for Q1 2022 were both ¥0.45, up by 25.00% compared to the same period last year[9] - The company reported a total comprehensive income of ¥53,801,911.59 for Q1 2022, compared to ¥43,292,471.03 in Q1 2021, reflecting a growth of 24.3%[36] Cash Flow - The net cash flow from operating activities was ¥37,228,404.83, showing a significant increase of 32.50% year-on-year[6] - The company reported an increase in cash flow from operating activities primarily due to increased sales receipts[14] - Total cash inflow from operating activities amounted to 320,187,766.56, compared to 278,516,932.87, indicating an increase of about 15%[40] - Cash outflow from operating activities totaled 282,959,361.73, up from 250,420,942.31, representing an increase of around 13%[40] - The net cash flow from investing activities was -512,688,220.48, an improvement from -871,690,550.73 in the previous period[40] - The net cash flow from financing activities was 29,861,694.44, a significant improvement from -257,062.53 in the previous period[42] Assets and Liabilities - The total assets at the end of Q1 2022 amounted to ¥2,861,798,804.03, which is a 3.12% increase from the end of the previous year[9] - Total liabilities as of the end of the reporting period were ¥515,961,055.44, up from ¥483,601,755.82, reflecting a growth of 6.5%[34] - Total current liabilities increased from 432,458,963.97 RMB to 464,865,439.18 RMB, an increase of about 7.5%[28] - Total equity attributable to shareholders of the parent company was ¥2,345,837,748.59, an increase from ¥2,291,664,728.59, showing a growth of 2.4%[34] Shareholder Information - Total number of common stock shareholders at the end of the reporting period is 7,161[18] - The largest shareholder, Wang Ying, holds 41,900,000 shares, representing 34.89% of total shares[18] Research and Development - The company's R&D investment totaled ¥53,296,057.20, representing 19.82% of operating revenue, an increase of 0.93 percentage points year-on-year[9] - Research and development expenses for Q1 2022 amounted to ¥45,192,135.02, compared to ¥41,794,134.64 in Q1 2021, marking an increase of 8.6%[34] Inventory and Receivables - Accounts receivable decreased from 112,427,878.56 RMB to 94,449,255.47 RMB, a reduction of approximately 16%[25] - Inventory increased from 103,682,790.76 RMB to 121,148,058.49 RMB, an increase of about 16.8%[25] Non-Recurring Items - Non-recurring gains and losses for the period totaled ¥11,922,482.60, with government subsidies included amounting to ¥5,805,651.10[12]

Financial Performance - The company's operating revenue for 2021 was CNY 1,022,935,588, an increase of 10.96% compared to CNY 921,918,474 in 2020[27]. - The net profit attributable to shareholders for 2021 was CNY 232,427,615, representing a growth of 30.46% from CNY 178,161,834 in 2020[27]. - The net cash flow from operating activities was CNY 147,596,571, a decrease of 5.70% compared to CNY 156,524,544 in 2020[27]. - The company's total assets at the end of 2021 were CNY 2,775,266,484, reflecting a 9.66% increase from CNY 2,530,857,158 at the end of 2020[27]. - The company's net assets attributable to shareholders increased by 9.37% to CNY 2,291,664,728 at the end of 2021 from CNY 2,095,247,258 at the end of 2020[27]. - The basic earnings per share for 2021 were CNY 1.94, up 8.99% from CNY 1.78 in 2020[27]. - The company reported a total revenue of 49,026.73 million, with a net profit of 24,270.87 million for the reporting period[113]. - Net profit attributable to the parent company reached 232,427,600 RMB, with a year-on-year increase of 30.46%[145]. - Total assets at the end of the reporting period amounted to 2,775,266,500 RMB, an increase of 9.66% compared to the beginning of the period[145]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 20.41% in 2021 from 16.69% in 2020, an increase of 3.72 percentage points[27]. - Research and development (R&D) investment amounted to 208.74 million yuan, accounting for 20.41% of operating revenue, reflecting the company's commitment to innovation[40]. - R&D investment totaled ¥208,742,801.20, a 35.63% increase from the previous year, driven by an increase in personnel and experimental costs[92]. - The proportion of R&D investment to operating income rose to 20.41%, an increase of 3.71 percentage points compared to the previous year[92]. - The company has over 50 ongoing projects, with 20% being innovative drug projects, including one chemical new drug in Phase III clinical trials and one biological new drug in Phase I clinical trials[124]. - The company invests over 16% of its sales revenue annually in R&D, ensuring continuous innovation and development[123]. - The company has established a complete quality management system for drug development and commercial production, with its raw material drug factory certified by the US FDA and EU EMA[128]. - The company has launched 9 products in the anesthesia and analgesia field and has over 20 projects in the pipeline, establishing a competitive product line in this area[124]. Product Development and Pipeline - The company launched new products such as Dabiqagrel and Palifermin, contributing to sales growth[27]. - The company is advancing the clinical trials of several new drugs, including the completion of Phase II trials for the small molecule new drug Yaglitin Tablets and the initiation of Phase III trials[41]. - The company received registration certificates for three new drugs, including Dabigatran Etexilate Capsules, and submitted 16 registration applications for formulations and raw materials[42]. - The company has multiple Class 1 biopharmaceuticals in development, with the self-developed EP-9001A monoclonal injection having completed IND application and approved for Phase I clinical trials[64]. - The company has developed a unique abuse-deterrent formulation technology for the morphine and naloxone sustained-release capsule, which is the first of its kind approved by the National Medical Products Administration in China[100]. - The company is focusing on expanding its product pipeline with a variety of new drug candidates, including those targeting pain management and oncology[100]. Market and Competitive Position - The company has a strong market presence, with three of its major products ranking first in market share among public hospitals in key provinces and cities in China[76]. - The company focuses on high-end generic drugs, leveraging specialized technologies to develop products with technical barriers and policy thresholds[65]. - The company is actively expanding its international pipeline, particularly in the specialty antidote field, with EP-0084A&I receiving CGT qualification from the FDA in April 2021[68]. - The company is enhancing its sales model by improving its distribution network and academic promotion strategies to adapt to national drug procurement policies[70]. - The company plans to leverage national centralized procurement opportunities to enhance product sales potential and expand into secondary and tertiary markets[166]. Risks and Challenges - The company has detailed various risks and countermeasures in its annual report, emphasizing the importance of investor awareness[5]. - The company faces risks from national volume-based procurement and adjustments in medical insurance payments, which may lead to price reductions for some products[134]. - Future uncertainties in the global economic environment, particularly due to the COVID-19 pandemic and geopolitical tensions, may adversely affect the company's operations[143]. - The company faced risks related to industry policy changes and technological iterations, which could impact its operational strategies[140][141]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from Zhonghui Certified Public Accountants[6]. - The company's board of directors and supervisory board members have confirmed the accuracy and completeness of the annual report[6]. - The company does not have any non-operating fund occupation by controlling shareholders or related parties[7]. - The company has not violated any decision-making procedures regarding external guarantees[9]. - The company has not proposed any bonus shares or capital reserve transfers to increase share capital[6]. Strategic Initiatives - The company is focusing on key areas such as oncology, cardiovascular diseases, and diabetes, which are highlighted in the "14th Five-Year" plan for the pharmaceutical industry[193]. - The company is adapting to the national policy of centralized drug procurement, which emphasizes competition and the integration of similar drugs[196]. - The introduction of DRG/DIP payment reforms is expected to influence medical insurance payment methods and clinical practices, prompting the company to enhance its product portfolio[200]. - The company has signed cooperation agreements with innovative pharmaceutical companies to enhance its product pipeline and market competitiveness[46].

Financial Performance - The company's operating revenue for Q3 2021 was ¥274,735,003.12, representing a year-on-year increase of 15.53%[7] - The net profit attributable to shareholders for Q3 2021 was ¥68,732,494.54, showing a significant increase of 77.22% compared to the same period last year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥31,691,075.23, with an increase of 8.87% year-on-year[7] - The basic earnings per share for Q3 2021 was ¥0.57, up 46.15% compared to the same period last year[10] - Total operating revenue for the first three quarters of 2021 reached ¥773,436,181.18, an increase of 14.93% compared to ¥672,755,703.53 in the same period of 2020[35] - Net profit for the third quarter of 2021 was ¥186,075,903.15, up 48.82% from ¥124,861,472.73 in the third quarter of 2020[38] - Earnings per share for the third quarter were ¥1.55, compared to ¥1.34 in the same quarter of the previous year, reflecting a growth of 15.66%[40] - The company reported a significant increase in investment income to ¥14,453,402.64, compared to ¥3,811,178.13 in the previous year, marking a growth of 278.66%[38] Assets and Liabilities - The total assets at the end of the reporting period reached ¥2,740,283,925.73, reflecting an increase of 8.27% from the end of the previous year[10] - The company reported a total asset increase to CNY 2,740,283,925.73 as of September 30, 2021, up from CNY 2,530,857,158.85 at the end of 2020, representing an increase of approximately 8.26%[25] - Total liabilities amounted to ¥493,882,030.49, compared to ¥435,609,899.90 in the previous reporting period, reflecting an increase of 13.33%[34] - The company's total assets reached ¥2,740,283,925.73, up from ¥2,530,857,158.85, indicating a growth of 8.26%[34] - The company’s total current liabilities decreased significantly, with short-term borrowings reported at CNY 40,028,171.23 as of September 30, 2021[30] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥144,363,177.82, representing a substantial increase of 91.46% year-on-year[10] - Cash flow from operating activities was ¥815,557,529.00, an increase from ¥690,920,875.31 in the same period last year, showing a growth of 18.06%[42] - Cash received from operating activities totaled $909,989,358.80, an increase from $745,953,906.44[46] - Cash received from other operating activities was $75,577,372.28, compared to $49,226,830.50 last year[46] - Net cash flow from operating activities increased to $144,363,177.82, up from $75,402,330.31 year-over-year[46] Research and Development - Research and development expenses totaled ¥53,531,673.35 for the quarter, accounting for 19.48% of operating revenue, which is an increase of 1.08 percentage points year-on-year[10] - Research and development expenses increased to ¥147,822,178.55, representing a rise of 34.76% from ¥109,608,757.89 in the previous year[35] - The company has made significant progress in its drug development pipeline, with the phase II clinical trial of the drug Yogerletin showing effective control of HbA1c levels in patients with type 2 diabetes[20] - The company received approval for the clinical trial of EP-9001A injection, a novel monoclonal antibody drug targeting human nerve growth factor, indicating advancement in its oncology product line[21] Government Support and Investments - The company received government subsidies amounting to ¥42,496,440.88 during the quarter, contributing to the increase in net profit[11] - The company plans to change the use of CNY 61 million of unutilized fundraising for the marketing network construction project to increase capital for its wholly-owned subsidiary, ShuoDe Pharmaceutical[24] Inventory and Receivables - The company’s inventory increased to CNY 89,850,571.76 from CNY 84,029,013.29, reflecting a growth of approximately 6.67%[29] - The company’s receivables increased slightly, with accounts receivable at CNY 123,921,003.60 compared to CNY 121,298,288.19, showing a growth of about 2.15%[29] Cash and Cash Equivalents - Cash and cash equivalents decreased to CNY 210,384,310.95 from CNY 1,055,289,158.05, indicating a significant reduction of about 80.17%[25] - The company's cash and cash equivalents at the end of the period stood at $179,999,752.81, down from $1,412,759,103.07[48]

Financial Performance - The company reported a semi-annual revenue of RMB 0 million for the first half of 2021, indicating no revenue generation during this period[20]. - The company's operating revenue for the first half of the year reached ¥498,701,178.06, representing a 14.65% increase compared to ¥434,960,631.37 in the same period last year[27]. - Net profit attributable to shareholders was ¥117,343,408.61, a 36.32% increase from ¥86,076,789.80 year-on-year[27]. - The net cash flow from operating activities was ¥63,375,926.37, up 11.22% from ¥56,984,183.28 in the previous year[27]. - The company's total assets increased to ¥2,580,557,399.86, a 1.96% rise from ¥2,530,857,158.85 at the end of the previous year[27]. - The company reported non-recurring gains of ¥33,560,980.15, primarily from government subsidies and investment income[31]. - The company achieved a revenue of 49,870.12 million RMB, representing a year-on-year growth of 14.65%[105]. - The net profit attributable to the parent company was 11,734.34 million RMB, an increase of 36.32% compared to the previous year[105]. - The company’s cash flow from operating activities increased by 11.22% to 569.84 million, primarily due to increased revenue and cash receipts[135]. Research and Development - The R&D investment as a percentage of operating revenue rose to 18.91%, an increase of 3.77 percentage points compared to 15.14% in the previous year[30]. - The company has over 10 Class 1 innovative drugs in development, with 3 currently undergoing clinical trials, including the oral long-acting hypoglycemic drug, Yogeritin tablets, which has completed Phase II trials and is in the clinical summary stage[38]. - The company has successfully commercialized 26 high-end chemical drugs, including 4 domestic first-generic products and 15 that have passed consistency evaluation[35]. - The company is currently developing a monoclonal antibody injection (EP-9001A) targeting bone metastatic pain, with a total investment scale of ¥154.36 million[75]. - The company has completed 2 Phase II clinical trials and 1 Phase I clinical trial for its drug candidates, indicating significant progress in its R&D pipeline[75]. - The company has initiated a major new drug creation project under the supervision of the National Health Commission, focusing on innovative drug transfer and transformation[69]. - The company is focusing on expanding its product line in the cardiovascular and oncology sectors, with several new products in the pipeline[10][12]. - The company has received production approval for multiple products, including EP-0001C, which has a market value of approximately $2.68 billion and has overcome original research preparation process patents[10]. Corporate Governance and Compliance - The board of directors confirmed that the semi-annual report is accurate and complete, with no significant omissions or misleading statements[3]. - The report is unaudited, and the responsible persons have confirmed the authenticity of the financial report[5]. - There are no non-operational fund occupations by controlling shareholders or related parties reported[7]. - The company has not faced any violations in decision-making procedures regarding external guarantees[7]. - There are no special arrangements for corporate governance reported[6]. - The company emphasizes the importance of investor awareness regarding forward-looking statements and associated risks[6]. - The company has established internal control systems for environmental management, including waste management and hazardous waste disposal, ensuring compliance with relevant laws and standards[164]. - The company has committed to transparency and compliance with all relevant laws and regulations regarding related party transactions[199]. Environmental Responsibility - The company has committed to green development and sustainable practices, focusing on reducing emissions and ensuring compliance with environmental standards[175]. - The company has conducted regular environmental monitoring through qualified third-party units, with no instances of exceeding emission standards reported[170]. - The company has received environmental impact assessment approvals for various projects, indicating compliance with environmental regulations[166]. - The company has implemented emergency response plans for environmental incidents, which have been registered with local environmental authorities[169]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[171]. Market Strategy and Future Outlook - The company is actively pursuing strategic transformation towards innovation, with a focus on developing both innovative and generic drugs to enhance competitiveness in the pharmaceutical industry[52]. - The company is considering strategic acquisitions to enhance its product portfolio, with a target of acquiring two companies by Q4 2021[184]. - The company is focusing on enhancing its marketing system, resulting in continuous sales growth for key products like ibandronate sodium injection and caffeine citrate injection[114]. - The company provided an optimistic outlook for the next quarter, projecting a revenue increase of 20% to 1.44 billion[183]. - Future guidance includes maintaining a minimum growth rate of 15% for the next two fiscal years[183]. Shareholder Commitments - The company has committed to not transferring or entrusting the management of its shares for 36 months post-IPO, ensuring stability in shareholding[185]. - The company will adhere to regulations regarding share reduction, limiting any reduction to 1% of total shares in a 90-day period for centralized bidding and 2% for block trading[188]. - If the company's stock price falls below the issue price for 20 consecutive trading days within 6 months post-IPO, the lock-up period will automatically extend by 6 months[190]. - Shareholders are restricted to selling no more than 1% of the total shares held in any 90-day period through centralized bidding and no more than 2% through block trading[194]. - The company commits to adhering to all relevant laws and regulations regarding share transfers and reductions[193].